The present study was undertaken to determine whether urinary excretion of aquaporin-2 (UAQP-2) is of value to diagnose the pathological state of water retention and hyponatremia. UAQP-2 under ad libitum water drinking was 429 fmol/mg creatinine in the patients with water retention, a value significantly greater than that of 153 fmol/mg creatinine in the normal subjects. An acute oral water load test (20 mL/kg BW) was performed in 7 normal subjects (22-25 yr old) and 10 patients with water retention and hyponatremia (55-75 yr old). The percent excretion of the water load was only 30% in the patient group compared with 70% in the control group (P Ͻ 0.01). In the control group, minimal urinary osmolality was as low as 131 mosmol/kg H 2 O, which was responsible for the decrease in plasma arginine vasopressin (AVP) levels after the reduction in plasma osmolality. In the patient group, minimal urinary osmolality was 320 mosmol/kg H 2 O, and free water clearance remained below 0.6 mL/min after the water load. This impaired water excretion was consistent with the nonsuppressible levels of plasma AVP despite hypoosmolality. The nadir of UAQP-2 was obtained at 60 -90 min. The minimal UAQP-2 was reduced to 284 fmol/mg creatinine, a value significantly greater than that of 76 fmol/mg creatinine in the control group. Similar results were obtained in the 6 patients with hypopituitarism, who had impaired water excretion and marked hyponatremia. Water excretion was totally normalized after the replacement of hydrocortisone (excretion of water load, 31% vs. 102%; P Ͻ 0.01). Hydrocortisone replacement also significantly reduced the minimal UAQP-2 from 225 to 49 fmol/mg creatinine after the acute oral water load, a value comparable to that in the control subjects. These results indicate that UAQP-2 is a potent marker to diagnose the pathological state of impaired water excretion and hyponatremia, dependent upon AVP, in patients with water retention and hypopituitarism. (J Clin Endocrinol Metab 83: 4034 -4040, 1998) I MPAIRED water excretion occurs in patients with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH), liver cirrhosis with ascites, congestive heart failure, and adrenal insufficiency (1-8). In these clinical settings there is hyponatremia to various extents. Nonsuppressible release of arginine vasopressin (AVP) is found despite hypoosmolality, which should reduce AVP release to undetectable levels (1-11). Reversal of hyponatremia by specific antagonists of AVP provides conclusive evidence for the role of AVP in pathological states of water retention (9, 10, (12) (13) (14) .
after the water load. This impaired water excretion was consistent with the nonsuppressible levels of plasma AVP despite hypoosmolality. The nadir of UAQP-2 was obtained at 60 -90 min. The minimal UAQP-2 was reduced to 284 fmol/mg creatinine, a value significantly greater than that of 76 fmol/mg creatinine in the control group. Similar results were obtained in the 6 patients with hypopituitarism, who had impaired water excretion and marked hyponatremia. Water excretion was totally normalized after the replacement of hydrocortisone (excretion of water load, 31% vs. 102%; P Ͻ 0.01). Hydrocortisone replacement also significantly reduced the minimal UAQP-2 from 225 to 49 fmol/mg creatinine after the acute oral water load, a value comparable to that in the control subjects. These results indicate that UAQP-2 is a potent marker to diagnose the pathological state of impaired water excretion and hyponatremia, dependent upon AVP, in patients with water retention and hypopituitarism. (J Clin Endocrinol Metab 83: 4034 -4040, 1998) I MPAIRED water excretion occurs in patients with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH), liver cirrhosis with ascites, congestive heart failure, and adrenal insufficiency (1) (2) (3) (4) (5) (6) (7) (8) . In these clinical settings there is hyponatremia to various extents. Nonsuppressible release of arginine vasopressin (AVP) is found despite hypoosmolality, which should reduce AVP release to undetectable levels (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . Reversal of hyponatremia by specific antagonists of AVP provides conclusive evidence for the role of AVP in pathological states of water retention (9, 10, (12) (13) (14) .
In response to AVP, concentrated urine is produced by water reabsorption across the renal collecting duct (15) . Sasaki et al. (16, 17) recently cloned a complementary DNA of the apical collecting duct water channel, aquaporin-2 (AQP-2), from rat and human kidneys. AQP-2 is an AVPregulated water channel; it is translocated from the cytoplasmic vesicles to the apical plasma membranes, by shuttle trafficking, in collecting duct cells when the cells are stimulated by AVP (18 -20) , and is again redistributed into the cytoplasmic vesicles after removal of AVP stimulation (21) . Also, AQP-2 is in part excreted into the urine (16, 17) , which is measurable by RIA or Western blot using a specific antibody against AQP-2 (22, 23). We demonstrated that urinary excretion of AQP-2 is significantly increased by exogenous and endogenous AVP, and urinary AQP-2 excretion has a positive correlation with plasma AVP levels (22, 24, 25) . The measurement of urinary excretion of AQP-2 is an useful tool for diagnosing central diabetes insipidus in the hypertonic saline infusion test (24) .
The present study was therefore undertaken to determine whether urinary excretion of AQP-2 is of value to diagnose the pathological state of water retention and hyponatremia. We measured urinary excretion of AQP-2 by RIA in normal subjects and patients with impaired water excretion.
Subjects and Methods Subjects
Ten patients with water retention and 7 control subjects were studied. The control group had 7 normal volunteers, aged 22-25 yr; they were 6 males and 1 female. Profiles of the group of 10 patients are shown in Table 1 ; they were 6 males and 4 females whose ages ranged from 55-75 yr (mean Ϯ se, 67.1 Ϯ 3.8 yr). The mean serum sodium (Na) level was 128.6 Ϯ 3.8 mEq/L when the patients were admitted to Jichi Medical School Hospital. Urinary osmolality (Uosm) was as high as 468.2 Ϯ 115.1 mosmol/kg H 2 O despite the decrease in plasma osmolality (Posm). The plasma AVP level was 1.3 Ϯ 0.4 pg/mL, although Posm was reduced to 267.3 Ϯ 7.5 mosmol/kg H 2 O, and it was not significantly different from the value of 1.4 Ϯ 0.2 pg/mL in the control subjects (n ϭ 20) (26) . There was no abnormality in renal function. Two patients were diagnosed with SIADH whose adrenal function was normal. Two patients were diagnosed with the central salt-wasting syndrome. Patients 5-10 had decreased levels of plasma ACTH (8.7 Ϯ 2.3 pg/mL) and serum cortisol (2.6 Ϯ 0.8 g/dL) with reduced urinary excretion of 17-OHCS. These 6 patients were diagnosed with hypopituitarism. Particularly, isolated ACTH deficiency was found in the patients 6 and 7. The present study was approved by the ethical committee of Jichi Medical School Hospital for human study. We obtained informed consent from all subjects before they joined the present protocol.
Acute oral water load test
An acute water load test was carried out in two groups of subjects. After an overnight fast, the study was started at 0800 h. The subjects were allowed to drink water freely before the start of the present protocol. After urination, blood was taken. Thereafter, water (20 mL/kg) was given orally for 30 min. Thirty-minute urine collections were made during the 240-min observation period. Blood samples were collected at 60-min intervals for 240 min. Urine samples were subjected to measurements of urine volume, Uosm, and urinary excretions of creatinine and AQP-2. Posm and plasma AVP levels were determined in blood samples.
In addition, an acute oral water load test was performed in the six patients with hypopituitarism in the absence and presence of 20 mg hydrocortisone. Hydrocortisone was administered at 0500 h, and the oral water load test was started at 0800 h. The protocol was the same as that described above.
Uosm and Posm were measured by freezing point depression (model 3W2, Advanced Instrument, Needham Heights, MA). The concentrations of creatinine in urine samples were measured by automatic clinical analyzer (model 736, Hitachi, Tokyo, Japan). Plasma AVP levels were measured by RIA using AVP RIA kits (Mitsubishi Chemistry, Tokyo, Japan) (9). Urinary AQP-2 was determined as described below.
RIA of urinary AQP-2
The RIA of urinary AQP-2 was performed by the method described in our previous reports (22, 24) . Urinary AQP-2-like immunoreactivity was measured by a specific RIA that used the polyclonal antibody against a synthetic portion of the C-terminal of human AQP-2 raised in rabbits. A synthetic peptide (Tyr 0 -aquaporin-2[V257-A271]) corresponding to the 15-amino acid sequence of the C-terminal of AQP-2 was radioiodinated with iodine-125 (New England Nuclear, Boston, MA) by the chloramine-T method. For the assay, 0.1 mL of the urine sample (diluted 1-8 times) or a standard, 0.1 mL assay buffer [0.05 mol/L sodium phosphate (pH 7.4), 0.08 mol/L sodium chloride, 0.01 mol/L ethylenediamine tetraacetate, 0.5% BSA, 0.5% Nonidet P-40, and 0.01% sodium azide], and 0.1 mL of the antibody (final dilution, 1:12,000) were incubated at 4 C for 48 h, followed by the addition of 0.1 mL of the radiolabeled synthetic peptide (ϳ10,000 cpm) and further incubation at 4 C for 48 h. Bound and free quantities of radiolabeled ligand were separated by the double antibody method. The serial dilution curve of the urine samples was parallel to that of the standard (data not shown). Each sample was analyzed in duplicate. We changed the antibody against a 15-amino acid sequence of the C-terminal of human AQP-2 for the RIA, and the data shown in the present study were less than those that we previously reported (24) . For the antibody used in the present study, the intra-and interassay coefficients of variation were less than 10%. The minimal detectable quantity of AQP-2 was 0.86 pmol/tube, and an amount equivalent to 6.9 pmol/tube caused 50% inhibition of binding of the radiolabeled ligand.
Statistical analysis
Urine volume, Uosm, Posm, plasma AVP, and excretion of urinary AQP-2 values were expressed as the mean Ϯ se. All values were compared with two-way ANOVA and Fisher's t test. P Ͻ 0.05 was considered significant. Figure 1 shows the urinary excretion of AQP-2 in the normal volunteers and the patients with water retention Posm, Plasma osmolality; Uosm, urinary osmolality; UNa, urinary sodium; BUN, blood urea nitrogen; AVP, arginine vasopressin.
Results
under ad libitum water drinking. Urinary excretion of AQP-2 was 153.3 Ϯ 28.1 fmol/mg creatinine in the normal volunteers. Its excretion was 2.8-fold greater in the patients with water retention than that in the normal volunteers.
The results of an acute oral water load test are shown in Table 2 and Figs. 2 and 3. An acute oral water load (20 mL/kg) produced water diuresis in the control subjects, since the percent excretion of the water load was 70.2 Ϯ 7.8% during the 4-h observation period. As shown in Table 2 , the minimal Uosm was as low as 94.4 Ϯ 9.8 mosmol/kg H 2 O, which was responsible for the decrease in plasma AVP levels after the reduction in Posm. Water diuresis was evident, as the free water clearance (CH 2 O) significantly increased after the acute oral water load in the control subjects (Fig. 2) . In contrast, the percent excretion of the water load was only 29.9 Ϯ 4.6% in the patients with water retention, a value significantly less than that in the control subjects (P Ͻ 0.01). Basal levels of Uosm were 501.9 Ϯ 75.3 mosmol/kg H 2 O. The minimal Uosm was not as sufficiently reduced, as its value of 387.8 Ϯ 61.1 mosmol/kg H 2 O was significantly greater than that in the control subjects (P Ͻ 0.01). The free water clearance remained below 0.6 mL/min after the oral water load, as shown in Fig. 2 . This impaired water excretion was in concert with the nonsuppressible levels of plasma AVP despite the hypoosmolality in the patients with water retention.
Urinary excretion of AQP-2 after the acute oral water load is shown in Fig. 3 . Basal levels of urinary AQP-2 were 516.9 Ϯ 137.5 fmol/mg creatinine in the patients with water retention, which was significantly greater than that of 153.3 Ϯ 28.1 fmol/mg creatinine in the control subjects (P Ͻ 0.05). The maneuver of an acute oral water load gradually decreased urinary excretion of AQP-2, followed by the gradual increase toward the level before the start of the water load in both groups of subjects. The nadir was obtained at 60 -90 min and was significantly greater in the patients with water retention than that in the control subjects. As the nadir appeared at different times in individuals, the minimal urinary excretion of AQP-2 was determined (Fig. 3b) . The difference in the minimal urinary AQP-2 between the two groups of subjects was more evident. In the patients with water retention, the minimal urinary AQP-2 decreased to only 253.9 Ϯ 54.3 fmol/mg creatinine, a value significantly greater than that in the control subjects (P Ͻ 0.01). Next, we compared the acute oral water load test in the patients with hypopituitarism in the absence and presence of hydrocortisone replacement. The patients included four panhypopituitarism and two isolated ACTH deficiency. The results of an acute oral water load test are shown in Table 3 and Fig. 4 . Before treatment with hydrocortisone, the percent excretion of the water load was only 31.5 Ϯ 5.9% during the 4-h observation period. In contrast, hydrocortisone replacement enormously improved water excretion, as the percent excretion of the water load increased to 102.5 Ϯ 17.4% during the 4-h observation period. As shown in Table 3 , the minimal Uosm decreased to 108.5 Ϯ 8.0 mosmol/kg H 2 O in the patients treated with hydrocortisone, a value significantly lower than that in the untreated patients with hypopituitarism. There was no difference in the minimal levels of Posm and plasma AVP between the presence and absence of hydrocortisone. Figure 4 shows urinary excretion of AQP-2 after the acute oral water load in the patients with hypopituitarism. The exaggerated urinary excretion of AQP-2 throughout the 4-h observation period was evident in the absence of hydrocortisone replacement (Fig. 4a) . Both the basal and the nadir levels of urinary AQP-2 were high in the untreated patients with hypopituitarism. The minimal urinary excretion of AQP-2 was determined (Fig. 4b) , as the nadir appeared at different times. Hydrocortisone replacement significantly reduced the minimal urinary excretion of AQP-2 after the acute oral water load, as the minimal urinary AQP-2 excretions were 224.7 Ϯ 69.7 and 49.4 Ϯ 20.5 fmol/mg creatinine in the patients before and after hydrocortisone replacement (P Ͻ 0.05).
Discussion
The present study demonstrated that urinary excretion of AQP-2 was exaggerated in the patients with water retention compared to that in the normal subjects. The maneuver of an acute oral water load manifested the impaired water excretion and the persistently elevated urinary excretion of AQP-2 in the patients with water retention. Such increased urinary excretion of AQP-2 was linked with the nonsuppressible levels of plasma AVP despite hypoosmolality. In the patients with hypopituitarism, hydrocortisone replacement normalized renal water excretion and diminished the exaggerated urinary excretion of AQP-2 to levels comparable to those in the control subjects. This is in concert with suppressible levels of plasma AVP in the patients with hypopituitarism taking hydrocortisone.
Clinical and laboratory experiments have demonstrated that impaired ability to excrete a water load occurs in patients with SIADH, liver cirrhosis with ascites, congestive heart failure, and adrenal insufficiency. (1-8, 27 ) Persistent eleva-
Alteration in free water clearance in two groups of control subjects and patients with water retention in the acute oral water load. E, Control subjects (n ϭ 7); F, patients with water retention (n ϭ 10). *, P Ͻ 0.01; **, P Ͻ 0.05 (vs. control subjects). Values are the mean Ϯ SEM.
FIG. 3.
Changes in urinary excretion of AQP-2 (UAQP-2) in control subjects and patients with water retention after an acute oral water load. E, Control subjects (n ϭ 7); F, patients with water retention (n ϭ 10). a, Time course during the 4-h observation period. b, Basal, minimal, and last values of UAQP-2. *, P Ͻ 0.01; **, P Ͻ 0.05 (vs. control subjects). Values are mean Ϯ SEM.
tion of plasma AVP levels has been shown despite hypoosmolality, which should suppress the osmotic release of AVP to undetectable levels (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) 27) . These pathological states are associated with hyponatremia to a various extent. RIA of AVP enables reliable measurement of plasma AVP levels, but the extent that plasma AVP varies in pathological states of impaired water excretion is not as great. In most clinical settings, the nonsuppressible levels of plasma AVP are estimated to be relatively high compared to the reduced Posm (14, 26) . We are often faced with the dilemma of elucidating the exact role of AVP in the impaired renal excretion of water.
AQP-2 is the AVP-dependent water channel of collecting duct cells and is recycling between the cytoplasmic vesicles and the apical plasma membranes in the cells (18 -21, 28, 29) . Recently, AQP-2 is partly excreted into the urine, which is approximately 3% of AQP-2 in the collecting duct cells (22) (23) (24) (25) . In normal subjects, urinary excretion of AQP-2 is changeable in a wide range in physiological conditions, and its variation positively correlates with that of plasma AVP levels (24). Rai et al. (25) showed that there is no difference in urinary excretion of AQP-2 among the varying ages, ranging 24 -76 yr. The difference in basal levels of urinary excretion of AQP-2 was evident in three groups of subjects. Urinary excretion of AQP-2 was 2.8-fold greater in the patients with water retention than that in the normal subjects, and it was one eighth less in the patients with central diabetes insipidus than in the normal subjects (24) . The maneuver of an acute oral water load of 20 mL/kg BW totally suppressed plasma AVP levels and produced water diuresis in the normal subjects. Also, this maneuver reduced urinary AQP-2 excretion to 41.8 Ϯ 14.8 fmol/mg creatinine. In contrast, an acute water load test did not significantly produce water diuresis in the patients with water retention, as the percent excretion of the water load was markedly less and the nadir of Uosm was significantly higher than those in the control subjects. Similar results were obtained with urinary excretion of AQP-2. The minimal levels of urinary excretion of AQP-2 were significantly greater than those in the control subjects. Nonsuppressible levels of urinary excretion of AQP-2 were similar in the patients with SIADH and those with central salt-wasting syndrome. As shown in Table 2 , plasma AVP levels were not as high in the patients with impaired water excretion whose Posm was hypotonic. Although an acute oral water load further decreased Posm, plasma AVP levels were not suppressed to undetectable levels in these patients. Therefore, there was no correlation between plasma AVP levels and urinary excretion of AQP-2 in the patients with water retention. The finding of the exaggerated urinary excretion of AQP-2 may be tightly linked with the up-regulation of AQP-2 messenger ribonucleic acid expression in the kidneys in the experimental models of SIADH, liver cirrhosis, and congestive heart failure (30 -33). As mentioned above, the antidiuretic action of AVP is dominant, and the impaired water excretion may not solely depend upon the plasma level of AVP. The antidiuretic action of AVP is a key to augment antidiuresis, because the exaggerated urinary excretion of AQP-2 reflected the action of AVP in collecting duct cells. These findings therefore indicate that urinary excretion of AQP-2 accounts for the cellular action of AVP in renal collecting duct cells and is a potent marker for the diagnosis of water metabolism dependent upon AVP. In the present study urinary excretion of AQP-2 was exaggerated in the patients with hypopituitarism, which was closely linked with the impaired water excretion. After hydrocortisone replacement, renal water excretion was normalized, and urinary excretion of AQP-2 was reduced to levels comparable to those in control subjects. In the last 2 decades clinical and laboratory studies have demonstrated the involvement of AVP in impaired water excretion and hyponatremia in primary and secondary adrenal insufficiency (8, 34 -37) . Plasma levels of AVP were relatively elevated despite hypoosmolality in the patients with primary and secondary adrenal insufficiency and the adrenalectomized animals (8, 34 -37) . Hypothalamic AVP messenger ribonucleic acid expression was increased in the animals after adrenalectomy, and corticosterone replacement reduced its expression to that in the sham-operated animals (38, 39) . Also, the administration of an AVP antidiuretic antagonist remarkably improved renal water excretion in the adrenalectomized rats receiving deoxycorticosterone (40) . The measurement of urinary excretion of AQP-2 strongly supported the pathological role of AVP in the impaired water excretion in these adrenal insufficiency. Hydrocortisone treatment decreased the exaggerated urinary AQP-2 excretion to the normal value and normalized water excretion in the patients with hypopituitarism. These results indicate that urinary excretion of AQP-2 participates in the understanding of AVP dependency and that AVP plays a major role in the impaired water excretion in hypopituitarism, particularly in pituitary-adrenal hypofunction.
In conclusion, we demonstrated that exaggerated urinary excretion of AQP-2 was found in the patients with water retention and remained high after an acute oral water load. Similar results were obtained in the group of patients with hypopituitarism. However, hydrocortisone replacement decreased urinary excretion of AQP-2 to the normal value, in association with the normalization of renal water excretion. These results indicate that urinary excretion of AQP-2 is a potent marker for the diagnosis of impaired water excretion, dependent upon AVP, in the patients with water retention and hypopituitarism.
